2022
MR Imaging–Based In Vivo Macrophage Imaging to Monitor Immune Response after Radiofrequency Ablation of the Liver
Santana J, Petukhova-Greenstein A, Gross M, Hyder F, Pekurovsky V, Gottwald L, Boustani A, Walsh J, Kucukkaya A, Malpani R, Madoff D, Goldberg S, Ahmed M, Joshi N, Coman D, Chapiro J. MR Imaging–Based In Vivo Macrophage Imaging to Monitor Immune Response after Radiofrequency Ablation of the Liver. Journal Of Vascular And Interventional Radiology 2022, 34: 395-403.e5. PMID: 36423815, PMCID: PMC11042914, DOI: 10.1016/j.jvir.2022.11.013.Peer-Reviewed Original ResearchConceptsImmune responseT1-weighted MRPrussian blue stainingRadiofrequency ablationRF ablationC57BL/6 wild-type miceMR imagingDose-escalation studyLocal immune responseMass cytometryWild-type miceRadiological-pathological correlationBlue stainingT1-weighted MR imagingHepatic radiofrequency ablationCD68 antibodyUntreated lobeVivo doseHepatic RF ablationVivo macrophagesMacrophagesMiceMR imaging scannerCoagulation areaCD68MR Imaging Biomarkers for the Prediction of Outcome after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic Features
Petukhova-Greenstein A, Zeevi T, Yang J, Chai N, DiDomenico P, Deng Y, Ciarleglio M, Haider SP, Onyiuke I, Malpani R, Lin M, Kucukkaya AS, Gottwald LA, Gebauer B, Revzin M, Onofrey J, Staib L, Gunabushanam G, Taddei T, Chapiro J. MR Imaging Biomarkers for the Prediction of Outcome after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic Features. Journal Of Vascular And Interventional Radiology 2022, 33: 814-824.e3. PMID: 35460887, PMCID: PMC9335926, DOI: 10.1016/j.jvir.2022.04.006.Peer-Reviewed Original ResearchConceptsProgression-free survivalPoor progression-free survivalLiver Imaging ReportingHepatocellular carcinomaMR imaging biomarkersRadiomics signatureRadiofrequency ablationRadiomic featuresImaging biomarkersImaging ReportingFirst follow-up imagingMedian progression-free survivalRF ablationEarly-stage hepatocellular carcinomaPretreatment magnetic resonanceFirst-line treatmentMultifocal hepatocellular carcinomaSelection operator Cox regression modelTherapy-naïve patientsEarly-stage diseaseKaplan-Meier analysisCox regression modelLog-rank testFollow-up imagingPrediction of outcome
2017
Science to Practice: Molecular-targeted Drug Delivery in Combination with Radiofrequency Ablation of Liver Cancer: A Magic Bullet?
Adam LC, Murali N, Chapiro J, Geschwind JF. Science to Practice: Molecular-targeted Drug Delivery in Combination with Radiofrequency Ablation of Liver Cancer: A Magic Bullet? Radiology 2017, 285: 333-335. PMID: 29045226, PMCID: PMC5673055, DOI: 10.1148/radiol.2017171527.Peer-Reviewed Original ResearchConceptsRadiofrequency ablationRF ablationHepatocellular carcinoma mouse modelTechnical success rateSurvival end pointsChemotherapeutic drug concentrationsCarcinoma mouse modelAnimal tumor modelsTumor-penetrating peptideClinical outcomesTarget lesionsDrug delivery systemsLiver cancerMouse modelTumor modelEnd pointDrug concentrationsDrug deliverySuccess rateTumor treatmentToxic effectsDelivery systemAblationMagic bulletLesions
2015
Science to Practice: The Changing Face of Local Tumor Therapies-Do We Have to Think Systemically When Treating Cancer Locally?
Chapiro J, Geschwind JF. Science to Practice: The Changing Face of Local Tumor Therapies-Do We Have to Think Systemically When Treating Cancer Locally? Radiology 2015, 276: 315-7. PMID: 26203703, PMCID: PMC4520212, DOI: 10.1148/radiol.2015150451.Peer-Reviewed Original Research